Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026 Halle (Saale) / Munich,…
Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales of Olverembatinib increased 81% year-over-year…
Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day…
2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed…
VANCOUVER, British Columbia and AUSTIN, Texas, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Inspire Semiconductor Holdings Inc. (“InspireSemi” or the “Company”)…
January 12, 2026 10:30 ET | Source: BridgeBio Pharma, Inc. - Preliminary unaudited Q4 and Full Year 2025 net Attruby® product…
MARKHAM, Ontario, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (the “Company”), today announced several material corporate developments, including…
STAFFORD, Texas, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…
AUSTIN, Texas, Dec. 16, 2025 /PRNewswire/ -- Xojo, Inc., the developers behind Xojo—a powerful cross-platform development tool and programming language—…
November 02, 2025 19:00 ET | Source: HUTCHMED (China) Limited — HUTCHMED unveils its innovative ATTC platform, potentially providing precision…